SERUM ALBUMIN: AN INDEPENDENT INDICATOR IN GUILLAIN–BARRE SYNDROME PATIENTS RECEIVING TREATMENT OF PLASMAPHERESIS

A FAYAZ; WZ ABBASI; US BUTT; A AHMAD; . ABDULLAH; F AHMED

doi:10.54112/bcsrj.v2023i1.411

Authors

A FAYAZ Department of Neurology, Hayatabad Medical Complex Peshawar, Pakistan.
WZ ABBASI Department of Medicine, THQ Murree, Pakistan.
US BUTT Department of Medicine, Mayo Hospital Lahore / King Edward Medical University, Lahore, Pakistan.
A AHMAD Department of Internal Medicine, Allama Iqbal Memorial Teaching Hospital, Sialkot, Pakistan.
. ABDULLAH Department of Neurology t, Rehman Medical Institute, Peshawar, Pakistan
F AHMED Department of Internal Medicine, Lahore General Hospital, Pakistan.

DOI:

https://doi.org/10.54112/bcsrj.v2023i1.411

Keywords:

Serum Albumin, Guillain–Barre Syndrome, Plasmapheresis

Abstract

This study aimed to assess the role of serum albumin as an independent indicator in Guillain–Barre Syndrome patients receiving plasmapheresis treatment. This descriptive case series was conducted at Hayatabad Medical Complex Peshawar, Pakistan, from December 2022 to May 2023. Total 80 patients with GBS syndrome. Patients were divided into two groups equally. Group A patients had lower serum albumin, and group B had normal serum albumin. In both groups, serum albumin as an independent indicator was assessed. Chi-square and Independent T-tests were applied in both groups, keeping the P value less than 0.05. The mean age of the patients was 31.90±8.63 years. The frequency of male patients was 62.5%, while female patients were 37.5%. In group A, 27.5% of patients had good outcomes, while 75.5% had poor outcomes, while in group B, 57.5% had good outcomes, and 42.5% had outcomes. The outcome in group B was significantly better than in group A (P = 0.007). In the normal serum albumin group, the Guillain-Barre syndrome disability score was significantly lower after receiving plasmapheresis treatment than in patients with low serum albumin levels.

Downloads

Download data is not yet available.

References

Badshah, M., Shabbir, G., Nabi, S. F., and Ahmed, D. (2018). Association of serum albumin levels and guillain barre syndrome (gbs) outcome. Pakistan Journal of Neurological Sciences (PJNS) 13, 1-6.

Bernsen, R., De Jager, A., Schmitz, P., and Van der Meché, F. (1999). Residual physical outcome and daily living 3 to 6 years after Guillain-Barré syndrome. Neurology 53, 409-409.

Chiò, A., Calvo, A., Bovio, G., Canosa, A., Bertuzzo, D., Galmozzi, F., Cugnasco, P., Clerico, M., De Mercanti, S., and Bersano, E. (2014). Amyotrophic lateral sclerosis outcome measures and the role of albumin and creatinine: a population-based study. JAMA neurology 71, 1134-1142.

Dirlikov, E., Major, C. G., Medina, N. A., Lugo-Robles, R., Matos, D., Muñoz-Jordan, J. L., Colon-Sanchez, C., Garcia, M., Olivero-Segarra, M., and Malave, G. (2018). Clinical features of Guillain-Barré syndrome with vs without Zika virus infection, Puerto Rico, 2016. JAMA neurology 75, 1089-1097.

Fokke, C., van den Berg, B., Drenthen, J., Walgaard, C., van Doorn, P. A., and Jacobs, B. C. (2014). Diagnosis of Guillain-Barré syndrome and validation of Brighton criteria. Brain 137, 33-43.

Fokkink, W.-J. R., Walgaard, C., Kuitwaard, K., Tio-Gillen, A. P., van Doorn, P. A., and Jacobs, B. C. (2017). Association of albumin levels with outcome in intravenous immunoglobulin–treated guillain-barré syndrome. Jama Neurology 74, 189-196.

Frenzen, P. (2008). Economic cost of Guillain-Barré syndrome in the United States. Neurology 71, 21-27.

Govoni, V., and Granieri, E. (2001). Epidemiology of the Guillain-Barré syndrome. Current opinion in neurology 14, 605-613.

Guillain, G., Barré, J., and Strohl, A. (1999). Radiculoneuritis syndrome with hyperalbuminosis of cerebrospinal fluid without cellular reaction. Notes on clinical features and graphs of tendon reflexes. 1916. In "Annales de medecine interne", Vol. 150, pp. 24-32.

Hughes, R. A. (2017). Is serum albumin associated with Guillain-Barré syndrome outcomes? JAMA neurology 74, 151-153.

HUSSAIN, J., SAQIB, M., SOHAILKHAN, F. J., MARWAT, S., and KHAN, N. (2018). Determine Serum Albumin as an Independent Biomarker for Clinical Outcome in Plasmapheresis Treated GBS Patients. Methods 2020.

Kuo, H. C., Liang, C. D., Wang, C. L., Yu, H. R., Hwang, K. P., and Yang, K. D. (2010). Serum albumin level predicts initial intravenous immunoglobulin treatment failure in Kawasaki disease. Acta paediatrica 99, 1578-1583.

Rajabally, Y. A., and Uncini, A. (2012). Outcome and its predictors in Guillain–Barré syndrome. Journal of Neurology, Neurosurgery & Psychiatry 83, 711-718.

Shahrizaila, N., Lehmann, H. C., and Kuwabara, S. (2021). Guillain-Barré syndrome. The lancet 397, 1214-1228.

Wakerley, B. R., and Yuki, N. (2015). Mimics and chameleons in Guillain–Barré and Miller Fisher syndromes. Practical neurology 15, 90-99.

Willison, H. J., Jacobs, B. C., and van Doorn, P. A. (2016). Guillain-barre syndrome. The Lancet 388, 717-727.

Yuki, N., and Hartung, H.-P. (2012). Guillain–barré syndrome. New England Journal of Medicine 366, 2294-2304.

Yuki, N., Taki, T., Inagaki, F., Kasama, T., Takahashi, M., Saito, K., Handa, S., and Miyatake, T. (1993). A bacterium lipopolysaccharide that elicits Guillain-Barré syndrome has a GM1 ganglioside-like structure. The Journal of experimental medicine 178, 1771-1775.